2025-10-31 06:44:27
Latest Post
SMC Global Securities Ltd Q2 FY2025-26 consolidated net profit declines to Rs. 20.65 crores
Rajoo Engineers Ltd Q2FY26 consolidated profit at Rs. 14.18 crores
Inventurus Knowledge Solutions Ltd consolidated Q2 FY2025-26 PAT climbs to Rs. 180.71 crores
IFB Industries Ltd consolidated PAT for Q2FY26 jumps to Rs. 50.79 crores
Share India Securities Ltd consolidated Q2 FY26 net profit at Rs. 92.91 crores
Stock Report
Jenburkt Pharmaceuticals Ltd posts net profit of Rs. 5.43 crore in Q3FY23
Posted On : 2023-02-07 22:36:09( TIMEZONE : IST )
JENBURKT PHARMACEUTICALS LTD. has reported Standalone financial results for the period ended December 31, 2022.
Financial Results (Q3 FY2023) - QoQ Comparison
The company has reported total income of Rs. 36.0295 crores during the period ended December 31, 2022 as compared to Rs. 37.1136 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs. 5.4338 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. 6.8662 crores for the period ended September 30, 2022.
The company has reported EPS of Rs. 11.84 for the period ended December 31, 2022 as compared to Rs. 14.96 for the period ended September 30, 2022.
| Financials | Q3 FY2023 | Q2 FY2023 | % Change |
| Total Income | ₹36.0295 crs | ₹37.1136 crs |  -2.92% |
| Net Profit | ₹5.4338 crs | ₹6.8662 crs | -20.86% |
| EPS | ₹11.84 | ₹14.96 | -20.86% |
Financial Results (Q3 FY2023) - YoY Comparison
The company has reported total income of Rs.36.0295 crores during the period ended December 31, 2022 as compared to Rs.34.2871 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.5.4338 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.6.2271 crores for the period ended December 31, 2021.
The company has reported EPS of Rs.11.84 for the period ended December 31, 2022 as compared to Rs.13.57 for the period ended December 31, 2021.
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹36.0295 crs | ₹34.2871 crs |  5.08% |
| Net Profit | ₹5.4338 crs | ₹6.2271 crs | -12.74% |
| EPS | ₹11.84 | ₹13.57 | -12.75% |
Financial Results (9 Months Ended FY2023) - YoY Comparison
The company has reported total income of Rs.105.4176 crores during the 9 Months period ended December 31, 2022 as compared to Rs.99.3608 crores during the 9 Months period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.18.2532 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.18.8484 crores for the 9 Months period ended December 31, 2021.
The company has reported EPS of Rs.39.77 for the 9 Months period ended December 31, 2022 as compared to Rs.41.07 for the 9 Months period ended December 31, 2021.
| Financials | 9 Months Ended FY2023 | 9 Months Ended FY2022 | % Change |
| Total Income | ₹105.4176 crs | ₹99.3608 crs | 6.10% |
| Net Profit | ₹18.2532 crs | ₹18.8484 crs | -3.16% |
| EPS | ₹39.77 | ₹41.07 | -3.17% |
Shares of JENBURKT PHARMACEUTICALS LTD. was last trading in BSE at Rs. 642.00 as compared to the previous close of Rs. 641.00. The total number of shares traded during the day was 1360 in over 10 trades.
The stock hit an intraday high of Rs. 642.00 and intraday low of 640.00. The net turnover during the day was Rs. 872400.00.
